NASDAQ:ASNS - Arsanis News Headlines

Sign in or create an account to add this stock to your watchlist.
$3.11 0.00 (0.00 %)
(As of 03/13/2019)
Previous Close$3.11
Today's Range$3.05 - $3.78
52-Week Range$1.15 - $28.69
Volume607,244 shs
Average Volume62,844 shs
Market Capitalization$45.53 million
P/E Ratio-0.19
Dividend YieldN/A
Beta1.8

Headlines

Arsanis (NASDAQ ASNS) News Headlines

Source:
DateHeadline
The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant OfferingThe Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
finance.yahoo.com - March 14 at 10:53 AM
X4 Pharmaceuticals Completes Merger with ArsanisX4 Pharmaceuticals Completes Merger with Arsanis
www.businesswire.com - March 13 at 5:22 PM
Arsanis Inc (ASNS) Given Consensus Recommendation of "Hold" by BrokeragesArsanis Inc (ASNS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 28 at 1:42 AM
Arsanis, Inc. (ASNS)Arsanis, Inc. (ASNS)
seekingalpha.com - January 26 at 9:42 AM
Arsanis files $150M mixed shelfArsanis files $150M mixed shelf
seekingalpha.com - January 26 at 9:42 AM
Arsanis Inc.Arsanis Inc.
www.barrons.com - December 13 at 4:26 PM
Arsanis Shares Soar on Recent Merger Agreement, Analysts Review and Target PriceArsanis Shares Soar on Recent Merger Agreement, Analysts Review and Target Price
finance.yahoo.com - December 3 at 9:58 AM
Arsanis, Inc. (ASNS) Pre-Market TradingArsanis, Inc. (ASNS) Pre-Market Trading
www.nasdaq.com - November 30 at 10:46 AM
X4 PharmaceuticalsX4 Pharmaceuticals
www.benzinga.com - November 29 at 10:19 AM
Arsanis, X4 Pharmaceuticals Announce Merger Deal With Rare Disease FocusArsanis, X4 Pharmaceuticals Announce Merger Deal With Rare Disease Focus
finance.yahoo.com - November 29 at 10:19 AM
Arsanis may face more layoffs after merger with X4 PharmaArsanis may face more layoffs after merger with X4 Pharma
www.bizjournals.com - November 28 at 10:14 AM
Arsanis rises sharply on acquisition by X4 PharmaceuticalsArsanis rises sharply on acquisition by X4 Pharmaceuticals
seekingalpha.com - November 27 at 4:05 PM
The Reason Healthcare Stocks Are Being Called Home By InvestorsThe Reason Healthcare Stocks Are Being Called Home By Investors
finance.yahoo.com - November 27 at 4:05 PM
SHAREHOLDER ALERT: WeissLaw LLP Investigates Arsanis, Inc.SHAREHOLDER ALERT: WeissLaw LLP Investigates Arsanis, Inc.
finance.yahoo.com - November 27 at 4:05 PM
Arsanis Vaults on Merger DiscussionsArsanis Vaults on Merger Discussions
www.baystreet.ca - November 27 at 10:35 AM
Arsanis, Inc (ASNS) to Merge with X4 PharmaceuticalsArsanis, Inc (ASNS) to Merge with X4 Pharmaceuticals
www.streetinsider.com - November 27 at 10:35 AM
Arsanis and X4 Pharmaceuticals Agree to MergerArsanis and X4 Pharmaceuticals Agree to Merger
finance.yahoo.com - November 27 at 10:35 AM
Arsanis Reports Financial Results for Third Quarter 2018Arsanis Reports Financial Results for Third Quarter 2018
finance.yahoo.com - November 9 at 10:06 AM
The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq DebutThe Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut
finance.yahoo.com - August 14 at 4:00 PM
Arsanis down 6% premarket on Q2 resultsArsanis down 6% premarket on Q2 results
seekingalpha.com - August 13 at 9:26 AM
Arsanis Reports Financial Results for Second Quarter 2018Arsanis Reports Financial Results for Second Quarter 2018
finance.yahoo.com - August 13 at 9:26 AM
Arsanis Enters Oversold TerritoryArsanis Enters Oversold Territory
finance.yahoo.com - July 16 at 9:21 AM
UPDATE: Piper Jaffray Downgrades Arsanis Inc (ASNS) to Neutral Following Removal of ASN100 From ModelUPDATE: Piper Jaffray Downgrades Arsanis Inc (ASNS) to Neutral Following Removal of ASN100 From Model
www.streetinsider.com - June 30 at 11:40 AM
INVESTOR ALERT: Investigation of Arsanis Announced by Holzer & HolzerINVESTOR ALERT: Investigation of Arsanis Announced by Holzer & Holzer
finance.yahoo.com - June 30 at 11:40 AM
Pre-Open Movers 06/28: (DRRX) (ZSAN) (CAVM) Higher; (ASNS) (PIR) (WBA) Lower (more...)Pre-Open Movers 06/28: (DRRX) (ZSAN) (CAVM) Higher; (ASNS) (PIR) (WBA) Lower (more...)
www.streetinsider.com - June 28 at 12:12 PM
Arsanis To Discontinue Its Phase 2 Clinical Trial Of ASN100 - Quick FactsArsanis To Discontinue Its Phase 2 Clinical Trial Of ASN100 - Quick Facts
www.nasdaq.com - June 28 at 12:12 PM
Arsanis, Inc (ASNS) Reports Discontinuation of its Phase 2 Clinical Trial of ASN100 for Prevention of S. aureus pneumoniaArsanis, Inc (ASNS) Reports Discontinuation of its Phase 2 Clinical Trial of ASN100 for Prevention of S. aureus pneumonia
www.streetinsider.com - June 28 at 12:12 PM
Arsanis to discontinue Phase 2 trial of pneumonia treatmentArsanis to discontinue Phase 2 trial of pneumonia treatment
seekingalpha.com - June 28 at 12:12 PM
Why Arsanis Shares Are BombingWhy Arsanis Shares Are Bombing
247wallst.com - June 28 at 12:12 PM
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100
finance.yahoo.com - June 28 at 12:12 PM
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 ProgramArsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
finance.yahoo.com - June 14 at 9:46 AM
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
finance.yahoo.com - April 20 at 4:06 PM
Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious DiseasesArsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - April 17 at 10:21 AM
Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal AntibodiesArsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies
finance.yahoo.com - April 4 at 5:33 PM
Arsanis to Present at the Needham & Company 17th Annual Healthcare ConferenceArsanis to Present at the Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 20 at 10:09 AM
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin AntibodiesArsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies
finance.yahoo.com - March 14 at 11:12 AM
Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017
finance.yahoo.com - March 9 at 11:02 AM
Arsanis to Present at the 38th Annual Cowen and Company Health Care ConferenceArsanis to Present at the 38th Annual Cowen and Company Health Care Conference
finance.yahoo.com - March 5 at 10:28 AM
What You Must Know About Arsanis Inc’s (NASDAQ:ASNS) ROEWhat You Must Know About Arsanis Inc’s (NASDAQ:ASNS) ROE
finance.yahoo.com - December 29 at 6:16 PM
Arsanis Announces Pricing of Initial Public OfferingArsanis Announces Pricing of Initial Public Offering
globenewswire.com - November 29 at 8:04 AM
Biotech Arsanis prices IPO at $10, below $15 to $17 price rangeBiotech Arsanis prices IPO at $10, below $15 to $17 price range
finance.yahoo.com - November 23 at 8:44 AM
Arsanis Announces Closing of Initial Public OfferingArsanis Announces Closing of Initial Public Offering
finance.yahoo.com - November 23 at 8:44 AM
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel